Showing results (3341-3350 of 5,702) with videos related to
Sort By:
Pageof 571
The Oncologist|April 5, 2011
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapyJennifer L Beaumont, Zeeshan Butt, Jeanfrancois Baladi, et al.The Oncologist|April 12, 2011
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibilitySusanna B Park, Cindy S Y Lin, Arun V Krishnan, et al.The Oncologist|April 12, 2011
Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based surveyMikkael A Sekeres, Jaroslaw P Maciejewski, Alan F List, et al.The Oncologist|April 7, 2011
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS studyMiguel Nogué, Antonieta Salud, Pilar Vicente, et al.The Oncologist|June 3, 2011
Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzleCarlo La Vecchia, Sharon H Giordano, Gabriel N Hortobagyi, et al.The Oncologist|June 3, 2011
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?Simona Soverini, Gianantonio Rosti, Ilaria Iacobucci, et al.The Oncologist|May 12, 2011
Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancerHendrik A Wolff, Lena-Christin Conradi, Markus Schirmer, et al.The Oncologist|June 11, 2011
Analysis of morbidity and clinical implications of laparoscopic para-aortic lymphadenectomy in a continuous series of 98 patients with advanced-stage cervical cancer and negative PET-CT imaging in the para-aortic areaCatherine Uzan, Amine Souadka, Sebastien Gouy, et al.The Oncologist|February 25, 2011
Targeted therapy in advanced well-differentiated neuroendocrine tumorsChandrajit P Raut, Matthew H KulkeThe Oncologist|February 25, 2011
Beyond traditional outcomes: improving quality of life in patients with renal cell carcinomaDavid CellaPageof 571